iTonic Holdings Ltd.
Key statistics
from XBRL data in SEC filingsAI briefing
from the latest 10-K, 10-Q and 8-K eventsiTonic Holdings Ltd is a Cayman Islands holding company in the electromedical and electrotherapeutic apparatus industry, operating primarily from Beijing, China, with shares listed on Nasdaq under ITOC.
What they do
iTonic Holdings Ltd (formerly Pheton Holdings Ltd) designs and markets electromedical and electrotherapeutic apparatus. The company operates through its subsidiaries in China and sells its products under the iTonic brand. Its principal executive offices are in Chaoyang District, Beijing.
Revenue drivers
- Electromedical devices — Primary revenue source; reported annual revenue of $523,031 in 2025, up from $448,196 in 2024 but below 2022's $679,777.
- Electrotherapeutic apparatus — Part of the product mix; contributes to overall sales but no separate segment breakdown was provided in the filing.
- China domestic market — Focus on Beijing and broader China market; no export revenue disclosed in the excerpt.
Recent performance
Revenue for fiscal 2025 was $523,031, a 16.7% increase from 2024's $448,196, but still below 2023's $628,591. Net loss widened to $5.1 million in 2025 from $660,588 in 2024. Operating cash flow was negative $3.2 million in 2025, deeper than the negative $775,000 in 2024. Diluted EPS was -$0.318 in 2025. As of December 31, 2025, the company had cash of $1.5 million and total shareholder equity of $6.1 million.
Strategy
The filing does not detail specific strategic initiatives beyond continuing operations and addressing the going concern. Management's plans to mitigate the going concern are described in Note 2 to the financial statements, but the excerpt does not detail them. The company has not indicated new product launches or market expansions in the provided text.
Risks
- Going concern risk — The auditor's report expresses substantial doubt about the company's ability to continue as a going concern due to recurring operating losses and negative cash flows.
- Persistent losses — Net losses have grown each year from $241,217 in 2023 to $5.1 million in 2025, indicating worsening profitability.
- Negative operating cash flow — Operating cash outflow increased from $63,636 in 2023 to $3.2 million in 2025, draining liquidity.
- Limited cash buffer — Cash and equivalents of $1.5 million may be insufficient to fund ongoing operations given the cash burn rate.
Outlook
No specific forward-looking statements are included in the excerpt. The going concern disclosure suggests management is preparing plans to secure additional funding or restructure operations, but details are not provided in the filing excerpt.